About Helios Biomedical
Helios Biomedical Inc. develops and manufactures acellular biologic devices for soft tissue repair and regeneration, and develops its own next-generation regenerative medicine products. Today we manufacture for several medical device companies.
Our technology grew out of early research at MIT, and our team has spent more than two decades learning how to make this class of biologic materials consistently, safely and at scale, with our manufacturing, quality and R&D teams working side by side on a single campus.
As demand from our customers grows, we are investing in more capacity, more automation and our own product pipeline, so that new biologic devices can be invented, tested and built for the benefit of patients worldwide.
Leadership
Yiannis Monovoukas, PhD, MBA
Founder and CEO
25 years of founding and leading biomedical companies, including the Helios Biomedical legacy companies TEI Biosciences and TEI Medical, two regenerative medicine companies that grew out of MIT and were both acquired in 2015.
Kevin Cornwell, PhD
Chief Scientific Officer
20 years of R&D in extracellular matrix biomaterials and device commercialization.
Peter Jackson, PhD
Chief Commercial Officer
30 years of commercial, operational and clinical development leadership in medical devices and biopharmaceuticals.
Ralph Jenkins
Chief Financial Officer
Former Managing Partner with EY, a global professional services organization.
Susan Reilly
VP of Quality
Recognized Quality Systems expert in the medical device industry with over 40 years of experience in quality systems, quality engineering, and regulatory compliance.